ArticleInfection and drug resistance2022
Prevalence and Trends in Antimicrobial Susceptibility Patterns of Multi-Drug-Resistance Non-Typhoidal
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Isolation and characterization of a novel lytic phage Artin targeting typhoidal and nontyphoidal Salmonella and evaluation of its antibacterial efficacy in food.Virology journal · 2026Article
- Article
- Prevalence, antimicrobial resistance, and genomic characterization of non-typhoidalVeterinary world · 2026Article
- Seven Years ofMicroorganisms · 2025Article
- Pan-drug, colistin, streptomycin, erythromycin, clindamycin resistant Salmonella enterica serovars isolated from slaughtered cattle and human in mansoura, Egypt.Annals of clinical microbiology and antimicrobials · 2025Article
- Antimicrobial Resistance and Phylogenetic Analysis of Multidrug-Resistant Non-TyphoidalAntibiotics (Basel, Switzerland) · 2025Article
- [Clinical and drug sensitivity characteristics of invasive non-typhoidalZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- The rise of non-typhoidalFrontiers in microbiology · 2025Article
- Emerging Strategies against Non-TyphoidalCurrent issues in molecular biology · 2024Review
- Genomic analysis ofMicrobiology spectrum · 2024Article
- Activity of a Bacteriophage Cocktail to ControlPHAGE (New Rochelle, N.Y.) · 2023Article
- Pathogen genomics and phage-based solutions for accurately identifying and controllingFrontiers in microbiology · 2023Article
- Therapeutic effects of oral administration of lyticFrontiers in microbiology · 2022Article
- Factors Associated with Multi-Drug-Resistant Non-TyphoidalInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Multi-drug resistance of non-typhoidal Methods: This retrospective study was extracted data of patients who had non-typhoidal Results: A total of 433 patients were identified. The most common age group was less than 15 years old (53.6%), with a median age of 12 years (IQR 57-4). Of these people, 61.1% had gastroenteritis and 36.7% had bacteremia. The most prevalent serogroups was C (28.6%). MDR-NTS rate was 52.8% (95% CI 39-44). The resistant rates were 43%, 32.8%, 22.8%, 6.7%, 4%, 0.45%, 0.45% for sulfamethoxazole/trimethoprim, amoxicillin-clavulanic acid, cefotaxime, ampicillin/sulbactam, piperacillin/tazobactam, imipenem and meropenem retrospectively. Resistant rates have been increasing, especially for ciprofloxacin (30%), which rose from 16.6% in 2011-2015 to 39.5% in 2016-2020 (prevalence rate ratio (PRR) 2.4,95% CI 1.51-3.72) and for ceftriaxone 25.4% which rose from 16.1% to 32% (PRR 2 95% CI 1.24-3.16). Ampicillin, norfloxacin, tetracycline, amikacin, gentamicin, and ceftazidime remained static at 62.3%, 49.5%, 33.2%, 15.2%, 8.8%, 2.8%, respectively. Conclusion: The prevalence of MDR-NTS has been increasing over the past decade, particularly those strains which demonstrate resistance to ciprofloxacin and ceftriaxone. Finding successful treatment requires a comprehensive selection of proper antimicrobials as well as close monitoring, especially in cases with severe infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.